Christopher King, MD
Critical Care Medicine · Falls Church, VANPI 1700874948
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by United Therapeutics Corporation at 53.0% of the total. Reporting peaked in 2023 at $27,063 and has fallen 63.4% since, to $9,912 in 2025. Among critical care medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $522.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$69K
- Actelion Pharmaceuticals US, Inc.$28K
- Boehringer Ingelheim$13K
- Merck$10K
- Genentech USA, Inc.$8K
- Genentech, Inc.$1K
- plus $1K from 13 others
Across 197 payments — averaging $11,397 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$1.5M
- Gilead$509K
- Roche Products Limited$215K
- Vertex$41K
- Rigel Pharmaceuticals, Inc.$16K
- Merck$45
What the payments were for
- Consulting fees$46,31335%
- Speaking & faculty fees$69,44853%
- Grants$1,0001%
- Travel & lodging$7,9966%
- Food & beverage$5,6734%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 113 | $69,203 |
| Actelion Pharmaceuticals US, Inc. | 34 | $28,473 |
| Boehringer Ingelheim | 17 | $13,219 |
| Merck | 16 | $9,580 |
| Genentech USA, Inc. | 11 | $7,627 |
| Genentech, Inc. | 1 | $1,000 |
| Eagle Pharmaceuticals, Inc. | 1 | $338 |
| Bayer | 17 | $326 |
| Insmed, Inc. | 16 | $307 |
| Gilead | 11 | $186 |
| Nestle Healthcare Nutrition Inc. | 3 | $60 |
| Astellas Pharma US Inc | 2 | $47 |
| Johnson & Johnson(2 entities) | 2 | $41 |
| AbbVie | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Advanced Respiratory, Inc | 1 | $18 |
| Shionogi Inc | 1 | $16 |
| Invivyd Inc | 1 | $15 |
| Sandoz | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$130,519 in reported general payments places this provider in the 95th percentile of 174 critical care medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 117 | $1,542,228 |
| Orenitram ErTreprostinil Diolamine | 38 | $871,195 |
| AdempasRiociguat | 46 | $728,840 |
| UptraviSelexipag | 24 | $559,847 |
| Tyvaso DpiTreprostinil | 19 | $429,776 |
| OpsumitMacitentan | 22 | $290,927 |
| LetairisAmbrisentan | 20 | $258,877 |
| EsbrietPirfenidone | 13 | $131,072 |
| Pirfenidone | 37 | $126,153 |
| AdcircaTadalafil | 17 | $92,949 |
| Ambrisentan | 26 | $73,648 |
| Tadalafil | 35 | $65,090 |
| Sildenafil Citrate | 83 | $36,837 |
| EliquisApixaban | 31 | $26,629 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $13,219 | $1,542,228117 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $28,473 | $850,77446 claims |
| BayerAdempas | $326 | $728,84046 claims |
| GileadLetairis | $186 | $258,87720 claims |
| Genentech USA, Inc.Esbriet | $7,627 | $131,07213 claims |
| United Therapeutics CorporationAdcirca | $69,203 | $92,94917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 174 critical care medicine providers in Virginia.
Other critical care medicine in Falls Church
- Oksana ShlobinFalls Church$375K
- Sami Abdul JawadFalls Church$193K
- Anju SinghalFalls Church$13K
- Duy DuongFalls Church$10K
- Mehul DesaiFalls Church$9K
- Christopher ThomasFalls Church$8K
- Markos KashiourisFalls Church$4K
- Ahmad Abdul-AzizFalls Church$2K
- James LantryFalls Church$1K
- Eric BonuraFalls Church$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.